Compare Sanofi SA (SNY) vs USA Rare Earth Inc. Class A Common Stock (USAR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs USA Rare Earth Inc. Class A Common Stock — how do they compare? Sanofi SA trades at $40.74 (market cap $96.38B), while USA Rare Earth Inc. Class A Common Stock trades at $10.06 (market cap $3.87B). The key difference: Sanofi SA is far larger — about 24.9× USA Rare Earth Inc. Class A Common Stock's market cap, and Sanofi SA pays a 6.08% dividend while USA Rare Earth Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and USA Rare Earth Inc. Class A Common Stock for 0 Days on average.
| SNY | USAR | |
|---|---|---|
Market Cap | $96.38B | $3.87B |
Volume | 5,335,342 | 20,993,390 |
Sector | Health | Basic Materials |
52-Week High | $52.34 | $33.68 |
52-Week Low | $39.12 | $10.32 |
Typical Hold Time | 94 Days | 0 Days |
Enterprise Value | $115.67B | $2.35B |
Dividend Yield | 6.08% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sanofi (SNY) trades at $39.12, down 1.56% with a bearish technical signal despite recent earnings beats. The company shows solid fundamentals with $46.72B revenue, 16.72% net margin, and reasonable valuation (P/E 21.71). Recent expansion of the Regeneron immunology alliance worth up to $8B signals growth potential beyond Dupixent, though 2026 forecasts indicate profit margin compression to 8.09%.
SNY presents a mixed outlook with strong current execution offset by future margin pressures. The bullish analyst consensus (44% Buy) and expanding immunology pipeline provide upside catalysts, while patent expirations and competitive threats pose medium-term risks. Cash flow volatility and debt levels require monitoring for long-term investors.
USA Rare Earth (USAR) trades at $11.265, down 4.7% today and near its 52-week low, reflecting persistent sector pressure. The company shows severe financial strain with a net income margin of -2,159.3% and negative cash flow from operations, though analyst consensus remains unanimously bullish with a $34.57 price target. Recent news highlights strategic investments in a $1.2 billion South Carolina facility and a $2.8 billion Brazil acquisition to build a mine-to-magnet supply chain, positioning it for long-term growth amid U.S. critical mineral initiatives.
The stock presents high risk due to extreme losses and cash burn but offers speculative upside if government funding and project milestones materialize. Key risks include execution challenges, reliance on future financing, and sector volatility. Investors should weigh the bullish analyst outlook against the company's current financial instability and macroeconomic headwinds affecting rare earth markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About USA Rare Earth Inc. Class A Common Stock
USA Rare Earth is building an integrated rare earth and permanent magnet supply chain spanning mining, metal and alloy production, and magnet manufacturing, with assets including the Round Top heavy rare earth deposit in Texas, a magnet manufacturing facility in Stillwater, Oklahoma, and metal-and-alloy producer Less Common Metals.
Read more on USAR →
